Understanding the role of MRAs in management of heart failure with Cardiologist Dr Rajeev Agarwala
By : Dr. Nandita Mohan
By : Dr Rajeev Agarwala
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-01-11 05:30 GMT | Update On 2022-01-11 09:29 GMT
Advertisement
Designated as an emerging epidemic in 1997, Heart failure is still a major clinical and public health concern. Many medicines previously used have gone into disrepute, while many others have been found to be useful.
Recently, 2021 update on the 2017 ACC expert consensus decision pathway has upgraded mineralocorticoid receptor antagonist (MRA) as a class 1 indication for the treatment of Heart failure with reduced ejection fraction.
Dr Rajeev Agarwala , an eminent cardiologist explains the role of MRAs in the management of heart failure.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.